New discovery in HIV vaccine response reveals surprising antibody behavior

Many vaccines work by introducing a protein to the body that resembles part of a virus. Ideally, the immune system will produce long-lasting antibodies recognizing that specific virus, thereby providing protection.

EC approves BeiGene’s Brukinsa combo for follicular lymphoma

Share this article The latest approval for follicular lymphoma treatment marks the fourth indication for Brukinsa in the European Union. Credit: fizkes / Shutterstock.com. The

November 20, 2023

Study identifies novel IgAN loci through pleiotropy

IgA nephropathy (IgAN) is a prevalent form of primary glomerulonephritis characterized by the deposition of IgA in the glomerular mesangium, leading to a spectrum of

January 3, 2025

Kite and Arcellx expand strategic collaboration

Share this article Kite has exercised its licence option for ACLX-001 of Arcellx in multiple myeloma. Credit: Nemes Laszlo / Shutterstock.com. Gilead company Kite has expanded

November 16, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.